Oncologic Outcomes of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Patients with Tumor-Nipple Distance Less than 2.0 cm

Emad Alsharif 1,2,* Jai Min Ryu 1,* Hee Jun Choi 3, Seok Jin Nam 4, Seok Won Kim 4, Jonghan Yu 4, Byung Joo Chae 4, Se Kyung Lee 4, and Jeong Eon Lee 1

1Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Division of Breast and Endocrine Surgery, Specialized Surgical Unit, King Abdullah Medical City, Makkah, Saudi Arabia
3Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea

ABSTRACT

Purpose: Although the indications for nipple-sparing mastectomy (NSM) are expanding, there remains a debate regarding the oncologic outcomes of patients treated with this method, especially those with a short tumor-nipple distance (STND). The aim of this study was to compare the long-term oncologic outcomes between patients with a long tumor-nipple distance (LTND) (≥ 2.0 cm) and those with STND (< 2.0 cm).

Methods: This was a retrospective study in which 266 patients who underwent NSM with immediate breast reconstruction between January 2008 and December 2014 at a single institution were enrolled. Of these patients, 21 were excluded because of loss to follow-up; thus, 245 patients were finally analyzed. All patients underwent preoperative breast magnetic resonance imaging and intraoperative frozen biopsy.

Results: The mean age of the patients was 42.4 years. STND was identified in 128 patients, and LTND in 117 patients. The mean follow-up period was 60.5 months. There were no significant differences between the 2 groups with respect to lymphovascular invasion, nuclear grade, nodal status, and subtype (p = 0.339, 0.372, 0.955, and 0.338, respectively). The STND group had significantly smaller tumors than the LTND group (p = 0.005). The median TND in the STND and LTND groups was 0.7 cm and 3.0 cm, respectively. Locoregional recurrence was reported in 4 patients in the STND group (3.1%) and 6 (5.1%) in the LTND group. A total of 3 patients died (1.2%; 2 in the STND group and one in the LTND group). There was no significant difference between the 2 groups with respect to disease-free survival or local recurrence-free survival (p = 0.334 and p = 0.477, respectively).

Conclusion: The long-term oncologic outcomes of patients treated with NSM did not significantly differ according to TND when the intraoperative frozen biopsy was negative for tumor cells.

Keywords: Breast neoplasms; Prognosis; Subcutaneous mastectomy
INTRODUCTION

The surgical treatment of breast cancer has undergone a paradigm shift from lifesaving surgery to balancing the consideration of aesthetics and oncologic outcomes [1,2]. Skin-sparing mastectomy (SSM) has become popular for the treatment of oncologic breast surgery, since it ensures better patient satisfaction and quality of life and exhibits similar oncologic outcomes to conventional mastectomy [3,4].

Owing to the nipple’s aesthetic value and restoration difficulty, nipple-sparing mastectomy (NSM) has gained popularity in the last decade, with better aesthetic and psychological outcomes [5]. Consequently, the eligibility of patients for NSM has been an important question. However, there exist no clear criteria for optimal patient selection for NSM. Factors such as tumor size (greater than 3.0 cm), histopathologic type, inflammatory breast cancer, direct skin or nipple involvement, tumor-nipple distance (TND; less than 2.0 cm), and clinically positive axillary lymph nodes have been suggested to reduce the oncologic safety of the procedure [6-8].

Although the indications for NSM are expanding, there remains a debate regarding TND. In a previous study with a 25.6-month follow-up period [9], the oncologic outcomes of NSM followed by immediate breast reconstruction (IBR) did not significantly differ according to TND. Here, we conducted a retrospective observational study using the same cohort to investigate the long-term outcomes of NSM with IBR according to TND.

METHODS

Study design

In total, 266 patients who underwent NSM with IBR between January 2008 and December 2014 at Samsung Medical Center, Seoul, Korea were enrolled in this retrospective study. Of these patients, 21 were excluded because of a loss to follow-up, so 245 patients were ultimately included in this study. The “short TND (STND) group” comprised patients with a TND < 2.0 cm, and the “long TND (LTND) group” comprised patients with a TND ≥ 2.0 cm. The primary endpoint was local recurrence-free survival (LRFS), and the secondary endpoint was disease-free survival (DFS), which included locoregional recurrence (LRR), distant metastasis (DM), and contralateral recurrence. Detailed information on patient enrollment can be found in a previous report [9]. The need for informed consent was waived because of the low risk posed by this investigation. This study adhered to the ethical tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Samsung Medical Center in Seoul, Korea (IRB No. 2018-07-102).

Preoperative evaluation

Patients were evaluated clinically to detect any signs of skin, nipple-areola complex (NAC), or nipple involvement that was clinically obvious by the presentation of a retracted nipple. Preoperative breast magnetic resonance imaging (MRI) was used to measure the TND of all eligible patients. Here, TND was measured as the shortest distance between the tumor and the base of the nipple in centimeters. The scans of the patients were reviewed by an expert and dedicated breast radiologist. The measurement of TND by preoperative MRI in patients who had undergone neoadjuvant chemotherapy (CTx) was conducted after completion of CTx. Patients with evidence of pathological complete response after neoadjuvant CTx were ultimately excluded from the study.
Intraoperative pathologic diagnosis
Intraoperative frozen biopsy was performed to confirm that the margin of resection at the nipple base was negative for tumor cells. The same frozen biopsy sections were sectioned perpendicularly for permanent biopsy. Intraoperative frozen sections were reviewed by dedicated breast pathologists. Patients whose intraoperative frozen sections were positive for invasive ductal or lobular carcinoma, ductal carcinoma in situ (DCIS), atypical ductal hyperplasia with necrosis, or lobular neoplasia underwent NAC removal and were excluded from this study.

Perioperative protocol
All patients underwent IBR following tumor removal. However, the choice of reconstructive option depended on the breast characteristics and desires of the patient, which were determined during preoperative consultations with the plastic surgeons. Neoadjuvant and adjuvant CTx, radiotherapy (RTx), and hormonal treatment (HTx) were decided by a multidisciplinary team including an expert breast medical oncologist. All specimens that underwent pathological examination were evaluated for tumor size, histopathology, nuclear grade (NG), lymphovascular invasion (LVI), hormone receptor (HR) status, and human epidermal growth factor receptor-2 (HER-2) expression.

Surgical technique
A 7.0 cm long radial incision was performed, which had the advantages of good exposure and bleeding control. The upper and lower flaps were raised and reached medially around the NAC. Retractors were applied superior and inferior to the NAC, and the nipple tissue was left hanging from the skin of the NAC. Using the blade, the nipple tissue just behind the dermis was sharply dissected at the nipple–dermal junction. The nipple tissue attached to the remaining glandular tissue was marked with ink and dissected for frozen nipple margin analysis. Using electrocautery, the glandular tissue was removed by subcutaneous dissection.

Follow-up
Postoperative follow-up visits typically occurred every 6 months (2 times per year) for a total of 5 years and then annually thereafter. During each visit, patients were examined clinically for evidence of LRR or DM and underwent both radiological and laboratory investigations. Radiological surveillance for LRR was conducted every 6 months by breast sonography and/or mammogram. Surveillance for DM was conducted annually by computed tomography of the chest and abdomen, and/or a bone scan. After 5 years of follow-up, patients were followed annually with breast sonography and/or mammogram.

Data collection
The demographic data and clinicopathological characteristics of the patients were collected from electronic medical records and comprised patient age, family history of breast cancer, genetic risk, body mass index (BMI), types of IBR and axillary surgery, neoadjuvant CTx, adjuvant CTx/radiation therapy, LRR, DM, and death. For patients with bilateral breast cancer, each breast was considered separately.

Statistical analysis
Patient characteristics were compared using independent t-tests for continuous variables and the χ² or Fisher’s exact test for categorical variables. Values are reported as mean ± standard deviation. Kaplan-Meier curves, with the corresponding results of log-rank tests, were constructed for DFS and LRFS. For all analyses, a p-value < 0.05 was considered statistically significant. All statistical analyses were executed using SAS version 9.
Institute, Cary, USA) and R3.0.3 (http://www.R-project.org; R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Overall, 245 patients who underwent NSM were included in this study. Of those, the LTND group comprised 117 patients, and the STND group comprised 128 patients. The proportion of the groups varied by year, as shown in Figure 1. The overall follow-up period ranged from 15 to 109 months, with a mean of 60.5 (± 19.9) months. The mean follow-up period in the LTND and STND groups was 63.9 (± 20.1) months and 56.9 (± 19.2) months, respectively.

Patient characteristics

The clinicopathological features of both groups are shown in Table 1. The mean age of the STND and LTND groups was 41.7 (± 8.0) years and 43.1 (± 7.2) years, respectively. Additionally, the mean BMI of the STND and LTND groups was 21.9 (16.9–29.6) kg/m² and 21.6 (16.6–31.3) kg/m², respectively. A positive family history of breast cancer was noted in 16 patients (12.5%) in the STND group, and 13 patients (11.1%) in the LTND group. There were no significant differences between the 2 groups with respect to LVI, NG, multiplicity, nodal status, HR status, or HER-2 status. The median TND of all patients, the STND group, and the LTND group was 1.7 cm (range: 0.0–7.0 cm), 0.7 cm, and 3.0 cm, respectively. The STND group had significantly smaller tumors than the LTND group (p = 0.005). However, there was no significant difference in lymph node involvement between the 2 groups (p = 0.950). No lymph node involvement was found in 97 patients (75.8%) in the STND group and 87 patients (74.4%) in the LTND group.

Medical treatment

The medical treatments administered to the patients are shown in Table 1. The administration of neoadjuvant CTx, adjuvant RTx, and adjuvant HTx was not clinically different between the 2 groups. A significantly smaller percentage of patients underwent adjuvant CTx in the STND group (39 patients; 30.5%) compared to the LTND group (62 patients; 53.0%) (p < 0.005).
Table 1. Clinicopathological characteristics of the STND and LTND groups

| Characteristic                                | STND (n = 128) | LTND (n = 117) | Total (n = 245) | p-value |
|-----------------------------------------------|----------------|----------------|-----------------|---------|
| Mean age (yr)                                 | 41.73 ± 7.97   | 43.13 ± 7.18   | 42.40 ± 7.62    | 0.151   |
| Mean follow-up durations (mo)                 | 56.9 ± 19.2    | 63.9 ± 20.1    | 60.5 ± 19.9     | 0.061   |
| BMI (kg/m²)                                   | 21.96 (16.9–29.6) | 21.6 (16.6–31.3) | 21.6 (16.6–31.3) | 0.998   |
| Family history of breast and/or ovarian cancer|                |                |                 | 0.890   |
| Yes                                           | 16 (12.5)      | 13 (11.1)      | 29 (11.8)       |         |
| No                                            | 112 (87.5)     | 104 (88.9)     | 216 (88.2)      |         |
| LVI                                           |                |                |                 | 0.399   |
| Yes                                           | 27 (21.1)      | 31 (26.5)      | 58 (23.7)       |         |
| No                                            | 101 (78.9)     | 86 (73.5)      | 187 (76.3)      |         |
| NG                                            |                |                |                 | 0.372   |
| Low                                           | 29 (22.7)      | 31 (27.9)      | 60 (24.5)       |         |
| Intermediate                                  | 71 (55.5)      | 62 (53.0)      | 133 (54.3)      |         |
| High                                          | 28 (21.9)      | 34 (29.1)      | 62 (25.3)       |         |
| Median TND (cm)                               | 0.7 (0–1.9)    | 3 (1–7)        | 1.7 (0–7)       | < 0.001 |
| Multiplicity                                  |                |                |                 | 0.459   |
| Yes                                           | 46 (35.9)      | 48 (41.0)      | 94 (38.4)       |         |
| No                                            | 82 (64.1)      | 68 (58.1)      | 150 (61.2)      |         |
| Unknown                                       | 0 (0.0)        | 1 (0.9)        | 1 (0.4)         |         |
| Histopathology                                |                |                |                 | 0.042   |
| IDC                                           | 74 (57.8)      | 85 (72.6)      | 159 (64.9)      |         |
| ILC                                           | 6 (4.7)        | 4 (3.4)        | 10 (4.1)        |         |
| DCIS                                          | 41 (32.0)      | 19 (16.2)      | 60 (24.5)       |         |
| Mixed                                         | 3 (2.3)        | 4 (3.4)        | 7 (2.9)         |         |
| Others                                        | 4 (3.2)        | 5 (4.3)        | 9 (3.6)         |         |
| Pathologic T stage                            |                |                |                 | < 0.001 |
| T0                                            | 44 (34.4)      | 19 (16.2)      | 63 (25.7)       |         |
| T1                                            | 61 (47.7)      | 53 (45.3)      | 114 (46.3)      |         |
| T2                                            | 20 (15.6)      | 39 (33.3)      | 59 (24.3)       |         |
| T3                                            | 3 (2.3)        | 6 (5.1)        | 9 (3.7)         |         |
| Pathologic N stage                            |                |                |                 | 0.955   |
| N0                                            | 97 (75.8)      | 87 (74.4)      | 184 (75.1)      |         |
| N1                                            | 27 (21.3)      | 25 (21.4)      | 52 (21.2)       |         |
| N2                                            | 2 (1.6)        | 3 (2.6)        | 5 (2.0)         |         |
| N3                                            | 2 (1.6)        | 2 (1.7)        | 4 (1.6)         |         |
| Pathologic stage                              |                |                |                 | 0.006   |
| 0                                             | 44 (34.4)      | 18 (15.4)      | 62 (25.3)       |         |
| I                                             | 47 (36.7)      | 50 (42.7)      | 97 (39.6)       |         |
| II                                            | 32 (25.0)      | 43 (36.8)      | 75 (30.6)       |         |
| III                                           | 5 (3.9)        | 6 (5.1)        | 11 (4.5)        |         |
| ER status                                     |                |                |                 | 0.179   |
| Positive                                      | 111 (86.7)     | 93 (79.5)      | 204 (83.3)      |         |
| Negative                                      | 17 (13.3)      | 24 (20.5)      | 41 (16.7)       |         |
| PR status                                     |                |                |                 | 0.146   |
| Positive                                      | 105 (82.0)     | 86 (73.5)      | 191 (78.0)      |         |
| Negative                                      | 23 (18.0)      | 31 (26.5)      | 54 (22.0)       |         |
| Her2-neu status                               |                |                |                 | 0.725   |
| Amplified                                     | 24 (18.8)      | 25 (21.4)      | 49 (20.0)       |         |
| Not amplified                                 | 104 (81.2)     | 92 (78.6)      | 196 (80.0)      |         |
| Subtype                                       |                |                |                 | 0.338   |
| Luminal A                                     | 98 (76.6)      | 80 (68.4)      | 178 (72.7)      |         |
| Luminal B                                     | 14 (10.9)      | 15 (12.6)      | 29 (11.8)       |         |
| HER-2                                         | 10 (7.8)       | 10 (8.5)       | 20 (8.2)        |         |
| TNBC                                          | 6 (4.7)        | 12 (10.3)      | 18 (7.3)        |         |
| Neoadjuvant chemotherapy                      | 6 (4.7)        | 7 (6.0)        | 13 (5.3)        | 0.868   |
| Adjuvant treatment                            |                |                |                 |         |
| Chemotherapy                                  | 39 (30.5)      | 62 (53.0)      | 101 (41.2)      | < 0.001 |
| Radiotherapy                                  | 13 (10.2)      | 17 (14.5)      | 30 (12.2)       | 0.396   |
| Hormonal therapy                              | 105 (82.0)     | 90 (76.9)      | 195 (79.6)      | 0.405   |

Values are presented as number (%), mean ± standard deviation or number (range).

STND = short tumor-nipple distance; LTND = long tumor-nipple distance; BMI = body mass index; LVI = lymphovascular invasion; NG = nuclear grade; TND = tumor-nipple distance; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; DCIS = ductal carcinoma in situ; ER = estrogen receptor; PR = progesterone receptor; HER-2 = human epidermal growth factor receptor-2; TNBC = triple negative breast cancer.
Surgical characteristics
The types of axillary surgeries and IBR performed are shown in Table 2. In total, 194 patients (79.2%) underwent sentinel lymph node biopsy—103 patients (80.5%) and 91 patients (77.8%) in the STND and LTND groups, respectively. Furthermore, permanent implant following tissue expander insertion was the most used reconstructive option in both the STND and LTND groups, with 83 patients (64.8%) and 86 patients (73.5%), respectively, choosing this procedure.

Oncologic outcomes
The description of events is shown in Table 3. There were 4 cases of LRR in the STND group—one case in the NAC and 3 cases in the skin and chest. In the LTND group, there were 6 cases of LRR—3 involving the NAC, 2 in the skin and chest wall, and one case of regional recurrence. Among these 10 patients with LRR, no patient exhibited DM and death with respect to recurrence in the contralateral breast, 2 cases were recorded in the STND group and one case was noted in the LTND group. Furthermore, DM was observed in 3 cases in the STND group (2 in the liver and one in the lymph nodes) and 6 cases in the LTND group (2 in the liver, one in the lung, one in the brain, and 2 in the lymph nodes). Mortality occurred in 3 cases in the study—2 STND group patients and one LTND group patient. Table 4 shows the LRR sites—4 patients experienced nipple recurrence, 5 patients experienced skin or chest wall recurrence, and only one patient showed regional recurrence. There were no significant differences between the 2 groups with respect to DFS or LRFS (log-rank test, \( p = 0.333 \) and \( p = 0.475 \), respectively) (Figure 2). There were also no significant differences with respect to DFS or LRFS stratified by DCIS and invasive cancer (log-rank test, \( p = 0.360 \) and 0.475 for DCIS and \( p = 0.374 \))

Table 2. Surgical treatment characteristics of the STND and LTND groups

| Characteristic                  | STND (n = 128) | LTND (n = 117) | Total (n = 245) | \( p \)-value |
|--------------------------------|----------------|----------------|----------------|--------------|
| Axillary surgery               |                |                |                | 0.718        |
| SLNB                            | 103 (80.5)     | 91 (77.8)      | 194 (79.2)     |              |
| ALND                            | 25 (19.5)      | 26 (22.2)      | 51 (20.8)      |              |
| Type of IBR surgery             |                |                |                | 0.293        |
| Implant based                   | 83 (64.8)      | 86 (73.5)      | 169 (69.0)     |              |
| LD                              | 6 (4.7)        | 2 (1.7)        | 8 (3.3)        |              |
| TRAM                            | 5 (3.9)        | 4 (3.4)        | 9 (3.7)        |              |
| DIEP                            | 31 (24.2)      | 25 (21.4)      | 56 (22.9)      |              |
| Others                          | 3 (2.3)        | 0 (0.0)        | 3 (1.2)        |              |

Values are presented as number (%). STND = short tumor-nipple distance; LTND = long tumor-nipple distance; SLNB = sentinel lymph node biopsy; ALND = axillary lymph node dissection; IBR = immediate breast reconstruction; LD = latissimus dorsi; TRAM = transverse rectus abdominis myocutaneous; DIEP = deep inferior epigastric perforator artery.

Table 3. Description of events

| Characteristics                  | STND (n = 128) | LTND (n = 117) | Total (n = 245) | \( p \)-value |
|---------------------------------|----------------|----------------|----------------|--------------|
| Total locoregional recurrence   | 4 (3.1)        | 6 (5.1)        | 10 (4.1)       | 0.714        |
| Nipple                          | 1 (0.8)        | 3 (2.6)        | 4 (1.6)        |              |
| Skin/chest wall                 | 3 (2.3)        | 2 (1.7)        | 5 (2.0)        |              |
| Regional                        | 0 (0.0)        | 1 (0.9)        | 1 (0.4)        |              |
| Contralateral breast recurrence | 2 (1.6)        | 1 (0.9)        | 3 (1.2)        | 1.000        |
| Distant metastasis              | 3 (2.3)        | 6 (5.1)        | 9 (3.7)        | 0.317        |
| Liver                           | 2 (1.6)        | 2 (1.7)        | 4 (1.6)        |              |
| Lung                            | 0 (0.0)        | 1 (0.9)        | 1 (0.4)        |              |
| Brain                           | 0 (0.0)        | 1 (0.9)        | 1 (0.4)        |              |
| LN                              | 1 (0.8)        | 2 (1.7)        | 3 (1.2)        |              |
| More than 2 sites               | 0 (0.0)        | 1 (0.9)        | 1 (0.4)        |              |
| Death                           | 2 (1.6)        | 1 (0.9)        | 3 (1.2)        | 1.000        |

Values are presented as number (%). STND = short tumor-nipple distance; LTND = long tumor-nipple distance; LN = lymph node.
and 0.420 for invasive cancer) (Figure 3). The univariate analysis for LRR did not exhibit a significant difference according to TND ($p = 0.919$, hazard ratio, 1.5420; 95% confidence interval, 0.4661–5.1009) (Table 5).

**DISCUSSION**

In the related previous study, no significant differences in complications, DFS, or LRFS were noted between patients with a TND < 2.0 cm and those with a TND ≥ 2.0 cm. However, that study was limited by its short follow-up period [10]. In this study, which included the same cohort of 245 patients who underwent NSM, our aim was to investigate the differences in long-term outcomes between the STND group, comprising 52.2% of patients, and the LTND group, comprising the remaining 47.8% of patients. This study reported 3 cases of mortality, 9 cases of DM, and ten cases of LRR. The current study analyzed the long-term follow-up data of patients who underwent NSM. The incidence of LRR involving the nipple, skin, or chest wall was 4.1%, with nipple recurrence occurring in 1.6% of patients; there was no significant difference between the 2 groups. These results lie within the average rate of previous studies (0.0%–25.7%), including those that specified STND as an exclusionary factor [1,11–14].

The United States National Comprehensive Cancer Network 2018 guidelines support the use of NSM in patients with breast cancer provided that it is to treat early-stage, biologically favorable, invasive cancers, and/or DCIS > 2.0 cm from the nipple, without any evidence of nipple involvement such as Paget’s disease or nipple discharge associated with malignancy and/or without evidence of malignant involvement of subareolar tissues on preoperative
However, our study suggests that NSM is oncologically safe even when a patient’s TND is < 2.0 cm. With the increased rate of NSM use in breast cancer, several studies have compared the oncologic safety profile of this technique with that of others. Gerber et al. reported no significant differences in complications between NSM, SSM, and modified radical mastectomy. Similarly, a 2011 meta-analysis by De La Cruz et al. exhibited no differences among the aforementioned 3 techniques with regards to survival or local recurrence.

Regarding NSM eligibility, TND was initially considered to be a critical criterion for patient selection, with some studies correlating NAC involvement and tumor distance from the NAC. Subsequently, several studies into NSM excluded patients according to TND, many considering 2.0 cm as the safe cutoff point. Conversely, other authors have considered expanding the inclusion criteria, though still imposing a minimum distance restriction. For instance, Jensen et al., Sacchini et al., and D’Alonzo et al. suggested that a TND

**Figure 3.** Kaplan-Meier analysis of DFS and LRFS in the STND and LTND stratified by ductal carcinoma in situ (A, B) and invasive cancer (C, D). DFS = disease-free survival; LRFS = local recurrence-free survival; STND = short tumor-nipple distance; LTND = long tumor-nipple distance.
of 1 cm is an appropriate minimum distance for NSM. Separately, in a study of 112 patients, Ponzone et al. [25] suggested that a TND of 5 mm on MRI is sufficient for NSM eligibility. Other studies pointed out the sensitivity of MRI in detecting NAC involvement; Mariscotti et al. [26] conducted a study using MRI and suggested a TND cutoff value of 10 mm.

The risk of involvement of the NAC increases as TND decreases [25,27,28]. The primary oncological concern of NSM is the risk of occult involvement of the NAC. However, Dent et al. [29] conducted a study of 195 patients who met the inclusion criteria for NSM. These patients were classified by NSM candidacy using a TND cutoff of 2.0 cm as seen in sonography and/or MRI, and were then reclassified using a TND cutoff of 1.0 cm. There was no significant difference in the rate of pathologically confirmed NAC involvement between candidates and non-candidates using a cutoff of either 2.0 cm or 1.0 cm, indicating that a TND of 1.0 cm should be safe for NSM.

Ultimately, a TND cutoff value of 2.0 cm is recommended for NSM, though this is less important than evidence of disease on the mandatory intraoperative nipple margin biopsy. In addition, the recurrence rates in the NAC after NSM are acceptably low (0.0%–3.7%), as reported by Galimberti et al. [30]. In our study, the NAC recurrence rate was 1.6%, affecting one case in the STND group and 3 cases in the LTND group, with no statistically significant difference noted between groups (log-rank test, p = 0.714).

There are a few limitations of the current study. The retrospective nature of this study may have given rise to selection bias. Furthermore, a greater number of patients in the STND and

| Variables          | Locoregional recurrence | hazard ratio | 95% CI    | p-value |
|--------------------|-------------------------|--------------|-----------|---------|
|                    | No  | Yes |               |          |         |
| TND                |     |     |               |          |         |
| STND (ref.)        | 123 | 4   | (2.6)        |         |         |
| LTND               | 111 | 6   | (47.4)       |         |         |
| Age                |     |     |               |          |         |
| ≥ 40 (ref.)        | 92  | 3   | (39.3)       | 1.5420  | 0.4661–5.1009 | 0.919 |
| < 40               | 142 | 7   | (60.7)       | 1.2595  | 0.3667–4.3263 | 0.338 |
| OP period          |     |     |               |          |         |
| 2008–2011 (ref.)   | 67  | 4   | (28.6)       | 1.6536  | 0.3427–7.9776 | 0.718 |
| 2012–2014          | 167 | 6   | (71.4)       |         |         |
| LVI                |     |     |               |          |         |
| Yes                | 57  | 1   | (24.4)       | 2.8591  | 0.3638–22.4659 | 0.319 |
| No (ref.)          | 177 | 9   | (75.6)       |         |         |
| NG                 |     |     |               |          |         |
| Low (ref.)         | 48  | 2   | (20.5)       | 1.1688  | 0.2359–5.7924 | 0.951 |
| Intermediate       | 127 | 5   | (54.3)       |         |         |
| High               | 59  | 3   | (25.2)       | 1.4063  | 0.2346–8.4282 | 0.490 |
| Pathologic stage   |     |     |               |          |         |
| 0 (ref.)           | 60  | 2   | (25.6)       | 1.8118  | 0.3501–9.3768 | 0.092 |
| I                  | 92  | 5   | (39.3)       |         |         |
| II                 | 71  | 3   | (30.3)       | 1.8796  | 0.3413–10.3923 | 0.530 |
| III                | 11  | 0   | (4.7)        | NA      | NA       |
| Subtype            |     |     |               |          |         |
| Luminal A (ref.)   | 170 | 7   | (72.6)       |         |         |
| Luminal B           | 27  | 2   | (11.5)       | 1.6782  | 0.3558–7.9148 | 0.571 |
| HER-2               | 19  | 1   | (8.1)        | 1.0743  | 0.1340–8.6123 | 0.380 |
| TNBC               | 18  | 0   | (7.7)        | NA      | NA       |

HR = hazard ratio; CI = confidence interval; TND = tumor-nipple distance; STND = short tumor-nipple distance; LTND = long tumor-nipple distance; OP = operative; LVI = lymphovascular invasion; NG = nuclear grade; HER-2 = human epidermal growth factor receptor 2; TNBC = triple negative breast cancer.
LTND groups had DCIS and underwent CTx, respectively, and these differences may have affected prognosis. However, the main strength of this investigation is that it is the first to compare long-term follow-up outcomes between STND and LTND patients who underwent NSM followed by IBR. Taken together, the long-term follow-up of patients treated with NSM revealed that oncological safety is not affected by TND. This suggests that patient eligibility for NSM for the treatment of breast cancer could be expanded to include more patients with tumors closely positioned to the nipple in preoperative MRI, if the intraoperative frozen biopsy of the nipple margin is free of tumor cells.

REFERENCES

1. Gerber B, Krause A, Dieterich M, Kundt G, Reimer T. The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study. Ann Surg 2009;249:461-8.
2. Peled AW, Duralde E, Foster RD, Fiscalsoini AS, Esererman LJ, Hwang ES, et al. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction. Ann Plast Surg 2014;72 Suppl 1:S48-52.
3. Sosin M, Gulla A, Potdevin L, Cox SE, Bartholomew AI, Seevaratnam S, et al. Timing of radiation therapy in nipple-sparing mastectomy influences outcomes and patient-reported quality of life. Breast J 2018;24:934-9.
4. Giannini V, Bianchi V, Carabalona S, Mazzetti S, Maggiorotto F, Kubatski F, et al. MRI to predict nipple-areola complex (NAC) involvement: an automatic method to compute the 3D distance between the NAC and tumor. J Surg Oncol 2017;116:1069-78.
5. Özkurt E, Tükenmez M, Güven E, Çelet Özden B, Öner G, Müslümanoğlu M, et al. Favorable outcome with close margins in patients undergoing nipple/skin sparing mastectomy with immediate breast reconstruction: 5-year follow-up. Balkan Med J 2018;35:84-92.
6. Chirappapha P, Sirichan P, Lertsithichai P, Thaweepworadej P, Sukarayothin T, Leesombatpaiboon M, et al. Nipple-areola complex sensation after nipple-sparing mastectomy. Plast Reconstr Surg Glob Open 2018;6:e1716.
7. Pek WS, Tan BK, Ru Ng YY, Kiak Mien Tan V, Rashid MZ, Kiat Tee Tan B, et al. Immediate breast reconstruction following nipple-sparing mastectomy in an Asian population: aesthetic outcomes and mitigating nipple-areolar complex necrosis. Arch Plast Surg 2018;45:229-38.
8. Endara M, Chen D, Verma K, Nahabedian MY, Spear SL. Breast reconstruction following nipple-sparing mastectomy: a systematic review of the literature with pooled analysis. Plast Reconstr Surg 2013;132:1043-54.
9. Ryu JM, Nam SJ, Kim SW, Lee SK, Bae SY, Yi HW, et al. Feasibility of nipple-sparing mastectomy with immediate breast reconstruction in breast cancer patients with tumor- nipple distance less than 2.0 cm. World J Surg 2016;40:2028-35.
10. Moris D, Kontos M. Nipple-sparing mastectomy with immediate breast reconstruction in breast cancer patients with tumour- nipple distance less than 2.0 cm: the jury is still out. World J Surg 2017;41:348.
11. Caruso F, Ferrara M, Castiglione G, Trombetta G, De Meo L, Catanuto G, et al. Nipple sparing subcutaneous mastectomy: sixty-six months follow-up. Eur J Surg Oncol 2006;32:937-40.
12. Jensen JA, Orringer JS, Giuliano AE. Nipple-sparing mastectomy in 99 patients with a mean follow-up of 5 years. Ann Surg Oncol 2011;18:1665-70.
13. Benediktsson KP, Perbeck L. Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients. Eur J Surg Oncol 2008;34:143-8.

PUBMED | CROSSREF

14. Petit JY, Veronesi U, Orecchia R, Curigliano G, Rey PC, Botteri E, et al. Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. Ann Oncol 2012;23:2053-8.

PUBMED | CROSSREF

15. NCCN Clinical Practice Guidelines in Oncology. Breast cancer, version 1. 2018. National Comprehensive Cancer Network (US). https://www.nccn.org/professionals/physician_gls/guidelines.asp. Accessed May 1, 2019.

16. Amara D, Peled AW, Wang F, Ewing CA, Alvarado M, Esserman LJ. Tumor involvement of the nipple in total skin-sparing mastectomy: strategies for management. Ann Surg Oncol 2015;22:3803-8.

PUBMED | CROSSREF

17. Haslinger ML, Sosin M, Bartholomew AI, Crocker A, Gulla A, Willey SC, et al. Positive nipple margin after nipple-sparing mastectomy: an alternative and oncologically safe approach to preserving the nipple-areolar complex. Ann Surg Oncol 2018;25:2303-7.

PUBMED | CROSSREF

18. De La Cruz L, Moody AM, Tappy EE, Blankenship SA, Hecht EM. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. Ann Surg Oncol 2015;22:3241-9.

PUBMED | CROSSREF

19. de Alcantara Filho P, Capko D, Barry JM, Morrow M, Pusic A, Sacchini VS. Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the Memorial Sloan-Kettering Cancer Center experience. Ann Surg Oncol 2011;18:3117-22.

PUBMED | CROSSREF

20. Stolier AJ, Sullivan SK, Dellacroce FJ. Technical considerations in nipple-sparing mastectomy: 82 consecutive cases without necrosis. Ann Surg Oncol 2008;15:1341-7.

PUBMED | CROSSREF

21. Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Merc-Bernstam F, Kuerer HM, et al. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol 2012;19:1137-44.

PUBMED | CROSSREF

22. Warren Peled A, Foster RD, Stover AC, Itakura K, Ewing CA, Alvarado M, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol 2012;19:3402-9.

PUBMED | CROSSREF

23. Sacchini V, Pinotti JA, Barros AC, Luini A, Pluchinotta A, Pinotti M, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J Am Coll Surg 2006;203:704-14.

PUBMED | CROSSREF

24. D’Alonzo M, Martincich L, Biglia N, Piscacane A, Maggiorotto F, Rosa GD, et al. Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. Eur J Cancer 2012;48:2311-8.

PUBMED | CROSSREF

25. Ponzone R, Maggiorotto F, Carabalona S, Rivolin A, Piscacane A, Kubitakzi F, et al. MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy. Eur J Cancer 2015;51:1882-9.

PUBMED | CROSSREF

26. Mariscotti G, Durando M, Houssami N, Berzovini CM, Esposito F, Fasciano M, et al. Preoperative MRI evaluation of lesion-nipple distance in breast cancer patients: thresholds for predicting occult nipple-areola complex involvement. Clin Radiol 2018;73:735-43.

PUBMED | CROSSREF

27. Cense HA, Rutgers EJ, Lopes Cardozo M, Van Lanschot JJ. Nipple-sparing mastectomy in breast cancer: a viable option? Eur J Surg Oncol 2001;27:521-6.

PUBMED | CROSSREF

28. Steen ST, Chang AP, Han SH, Vinstein AL, Yoon JL, Giuliano AE. Predicting nipple-areolar involvement using preoperative breast MRI and primary tumor characteristics. Ann Surg Oncol 2013;20:633-9.

PUBMED | CROSSREF

29. Dent BL, Miller JA, Eden DJ, Swistel A, Talmor M. Tumor-to-nipple distance as a predictor of nipple involvement: expanding the inclusion criteria for nipple-sparing mastectomy. Plast Reconstr Surg 2017;140:1e-8.e.

PUBMED | CROSSREF

30. Galimberti V, Vicini E, Corso G, Morigi C, Fontana S, Sacchini V, et al. Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications. Breast 2017;34 Suppl 1:S82-4.

PUBMED | CROSSREF